SCHEMBL26424288

SCHEMBL26424288

c1ccc(-c2ccc3c(c2)sc2cccc(-c4c5ccccc5c(-c5ccccc5)c5ccccc45)c23)cc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LIMK1 P53667 2/20 0.37
F9 P00740 2/20 0.37
MAPT P10636 2/20 0.35
RAB9A P51151 2/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
ALDH1A1 P00352 1/20 0.35
HPGD P15428 1/20 0.35
PIK3CA P42336 1/20 0.34
PI4KA P42356 1/20 0.34
PI4KB Q9UBF8 1/20 0.34
ALOX5 P09917 1/20 0.34
MCL1 Q07820 1/20 0.34
PTPN1 P18031 4/20 0.33
BRDT Q58F21 1/20 0.33
L3MBTL1 Q9Y468 2/20 0.33
ESR1 P03372 1/20 0.33
ESR2 Q92731 1/20 0.33
GPR3 P46089 1/20 0.32
CYP1A2 P05177 1/20 0.32
CYP3A4 P08684 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23427920 0.97 LIMK1 (0.36) LIMK1F9MAPTRAB9ASMN1; SMN2
SCHEMBL23427725 0.97 LIMK1 (0.36) LIMK1F9MAPTRAB9ASMN1; SMN2
SCHEMBL27331853 0.96 LIMK1 (0.36) LIMK1F9MAPTRAB9ASMN1; SMN2
SCHEMBL23427629 0.96 LIMK1 (0.36) LIMK1F9MAPTRAB9ASMN1; SMN2
SCHEMBL23427601 0.96 F9 (0.38) LIMK1F9MAPTRAB9ASMN1; SMN2
SCHEMBL24178657 0.94 F9 (0.40) LIMK1F9MAPTRAB9ASMN1; SMN2
SCHEMBL23427257 0.94 F9 (0.40) LIMK1F9MAPTRAB9ASMN1; SMN2
SCHEMBL23427115 0.94 F9 (0.40) LIMK1F9MAPTRAB9ASMN1; SMN2
SCHEMBL23427119 0.94 F9 (0.36) LIMK1F9MAPTRAB9ASMN1; SMN2
SCHEMBL23427728 0.93 F9 (0.35) LIMK1F9MAPTRAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230127291-A1 HETEROCYCLIC ARYLAMINE COMPOUND, ORGANIC ELECTROLUMINESCENT DEVICE AND DISPLAY PANEL WUHAN TIANMA MICROELECTRONICS CO., LTD. (CN) 2023-04-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230127291-A1 HETEROCYCLIC ARYLAMINE COMPOUND, ORGANIC ELECTROLUMINESCENT DEVICE AND DISPLAY PANEL OCIAD2, OCIAD1, AZI2 LIMK1 1525/4885F9 2171/4885MAPT 1685/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.